Find a Clinical Trial

Showing 11 - 20 of 26 Trials

  • A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05252416

    Population:

    Adult

    Phase:

    I/II
    This first-in-human study will evaluate the recommended dose, safety, and effects (good and bad) of an experimental drug, BLU-222, either alone or in combination with therapies approved for some types of cancer, including carboplatin, ribociclib, and fulvestrant, to find out if these are safe and effective ways to treat nonresectable (unable to be removed with surgery) advanced solid tumors, including ovarian, endometrial, and estrogen receptor positive (ER+) or human epidermal growth factor receptor 2 negative (HER2-) breast cancer. All subjects participating in this research study will...

  • A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05787587

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find out if the experimental study drug called IDE161 used alone is safe and helpful in solid tumors known to be caused by an error in genes that repair DNA. Cells have different ways to repair damaged DNA. Experimental means that the study drug has not been approved by any regulatory authorities, including the U.S. Food and Drug Administration (FDA) .IDE161 may block the ability of a protein called Poly(ADP-ribose) glycohydrolase (PARG) from properly functioning. PARG is an important protein in a different DNA repair pathway called Base Excision Repair (BER)...

  • Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05462717

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test a new drug called RMC-6291, to evaluate its safety at different doses, and to find out how the body processes it. RMC-6291 is a new experimental drug, which means that it is not approved by the US Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC- 6291 will be tested in humans. Are you Eligible? (Inclusion Criteria) Must be 18 year old or older - Life expectancy of more than 3 months - Subjects must be able to take the study drug and retain by mouth

  • A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

    Principal Investigator:

    Susan E. Bates, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04068194

    Population:

    Adult

    Phase:

    I/II
    This study is being done to answer the following question: Is M3814 in combination with radiation therapy and avelumab safe and tolerable in patients with advanced or metastatic cancers. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced or metastatic cancer. The usual approach is defined as care most people get for advanced or metastatic solid tumor. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you have a tumor which has spread to other parts of your body or that has advanced and...

  • A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors

    Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05585034

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to assess whether an investigational drug, called XmAb808, given in combination with pembrolizumab, has any effects on your cancer, to determine the best dose of XmAb808 to treat your cancer, and if it is safe and well tolerated. XmAb808 is an investigational drug being developed for the treatment of advanced solid tumors. An investigational drug is a drug that has not been approved by the U.S. Food and Drug Administration (FDA), the health authority that approves new medicines to be prescribed in the United States. Are you Eligible? (Inclusion Criteria) Subject...

  • A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05382559

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find out if ASP3082 is effective and safe as a treatment in advanced cancers with KRAS G12D mutation. ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. This is the first study where ASP3082 is being tested in humans. Are you Eligible? (Inclusion Criteria) Are you 18 years or older? Do you have locally advanced/unresectable or metastatic solid tumor with documented KRAS G12D mutation? Have you never been treated with another specific KRAS G12D inhibitor?

  • An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-dependent or Steroid-refractory Immune-Related Adverse Events due to Immune Checkpoint Blockade.

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04375228

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to determine the safety and effectiveness of two drugs, either rituximab or tocilizumab, in patients who develop side effects while on treatment with immunotherapy requiring prolonged steroids. Immune-related side effects are caused by activation of the immune system from treatment with immunotherapy. Both rituximab and tocilizumab have been given to patients with autoimmune diseases (diseases where the immune system is activated against normal organs). Immune-related side effects appear to closely mirror these autoimmune conditions. Are you Eligible? (Inclusion...

  • A Phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors

    Principal Investigator:

    Fabio M. Iwamoto, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04478279

    Population:

    Adult

    Phase:

    I/II
    With this research study, we want to find out which dose of ST101 is tolerable and effective for people with different types of cancer. We also want to see what the body does to ST101, where ST101 goes in the body, and how long it stays in the body. This study is the first time we have given ST101 to humans. Drugs that can only be used in research are sometimes called 'investigational drugs.' Investigational means the study drug/formulation/medical device being tested is not approved by the U.S. Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Are you at least 18...

  • The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Principal Investigator:

    Alexander Z. Wei, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT02693535

    Population:

    Adult

    Phase:

    II
    Many research studies are done to try to find the best way to treat patients with cancer. Researchers are working on new anticancer agents that are targeted to the genes in a person’s tumor. Genes are the basic “instruction book” for the cells that make up our bodies and are made out of DNA. DNA contains information that determines things such as eye and hair color. DNA is made up of long strands of repeating letters that form a code. The order of these letters in DNA is important. In the same way that a spelling mistake in a word could change its meaning (for example, mean...

  • Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients with Molecularly Selected Cancers (ATTACC)

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04972110

    Population:

    Adult

    Phase:

    I/II
    The study is being done to learn how safe and effective the study drug, RP- 3500, is when given with either niraparib or olaparib to treat advanced cancer. Niraparib and olaparib belong to a group of drugs called PARP inhibitors. These drugs are designed to block an enzyme called PARP which may stop cancer cells from growing. RP 3500 belongs to a class of drugs called ATR inhibitors that are design to stop cancer cells from growing. Are you Eligible? (Inclusion Criteria) Aged 18 years or older. Diagnosed with locally advanced or metastatic cancer. Have not received prior therapy with another...

Pages